Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Statement on FDA Approval of Shelf Life Extension for Company's COVID-19 Vaccine

06/11/2021 | 10:40am EDT

NEW BRUNSWICK, N.J. - We are pleased to confirm the U.S. Food & Drug Administration (FDA) has authorized an extension of the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine from 3 months to 4.5 months. The decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 4.5 months when refrigerated at temperatures of 36 - 46 degrees Fahrenheit (2 - 8 degrees Celsius). Expiration dates will be updated on www.vaxcheck.jnj. Vaccine providers should visit www.vaxcheck.jnj to confirm the latest expiration dates of our vaccine, including those currently available for administration throughout the U.S.

A single-shot vaccine that provides protection and prevents hospitalization and death is an important tool in the global fight against COVID-19. Evidence from our Phase 3 ENSEMBLE study demonstrates the efficacy of our single-shot COVID-19 vaccine, including against viral variants that are highly prevalent. Regardless of race and ethnicity, age, geographic location and comorbidities, these results remain consistent.

We continue to work with the U.S. government and health authorities to support the use of our vaccine, which plays an important role in combatting the pandemic, including among those who wish to be fully vaccinated with one shot.

Cautions Concerning Forward-Looking Statements

This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Contact:

T: 1800 22 8111

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
06/17JOHNSON & JOHNSONá : Eying border reopening, Mexico begins J&J vaccine rollout i..
AQ
06/17Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose
DJ
06/17US to Spend $3.2 Billion on COVID Treatments Research
MT
06/16ASTRAZENECAá : Second Phase of Covid-19 Vaccinations Begins
AQ
06/16EU Says Johnson & Johnson May Not Meet Vaccine Supply Commitment After Jabs C..
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15JOHNSON & JOHNSONá : Aspen to Dispatch 300 000 J&J Vaccines for Teachers
AQ
06/15JOHNSON & JOHNSONá : Donated US vaccines arrive for Mexican border cities
AQ
06/15THE LATEST : Johnson & Johnson shots arrive in Mexico from US
AQ
06/15FEDEXá : Makes its First COVID-19 Vaccine Delivery to Mexico, of 1.35 Million Jo..
MT
More news
Financials (USD)
Sales 2021 92 812 M - -
Net income 2021 22 227 M - -
Net Debt 2021 314 M - -
P/E ratio 2021 19,9x
Yield 2021 2,53%
Capitalization 435 B 435 B -
EV / Sales 2021 4,69x
EV / Sales 2022 4,39x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 183,67 $
Last Close Price 165,22 $
Spread / Highest target 23,5%
Spread / Average Target 11,2%
Spread / Lowest Target -4,37%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON4.98%435 090
ROCHE HOLDING AG12.75%328 768
PFIZER, INC.7.25%220 997
NOVARTIS AG2.73%210 424
ABBVIE INC.7.23%202 939
ELI LILLY AND COMPANY31.61%201 995